The Competitive Intelligence report Filgrastim &
Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF
Competitor Analysis describes product portfolios and R&D pipelines of
granulocyte colony stimulating factor (G-CSF) and GM-CSF products and product
candidates in regulated and in less regulated markets as of July 2015. Purchase
of the pdf report includes a 6-month online access to the data of the report
and any updates since the publication date. Credentials to access the database
will be sent by e-mail and allow online work with the project data to print or
export an individual report.
With 2014 sales of about US$ 6 bln, first and next
generation G-CSF products represent an attractive market size for biosimilar
proteins in regulated markets. Biosimilar filgrastim products have already been
introduced into the the European Union and now are also entering the US market.
Importantly, biosimilar products from Indian companies are among the approved
products indicating that Indian companies can fulfill Western standards of cGMP
manufacturing and cGCP development of at least relatively simple therapeutic
proteins such as filgrastim.
The report includes a compilation of currently
marketed branded and non-branded G-CSF and GM-CSF products in regulated and
less regulated markets for treatment of chemotherapy-induced neutropenia. The
report includes the market size of branded G-CSF products in 2014. In addition,
the report lists company-specific product portfolios and R&D pipelines of
G-CSF/GM-CSF products and projects. Competitor projects are listed in a tabular
format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
About
Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS,
but concise information about the pipeline of R&D projects for targets,
diseases, technologies and companies at low prices. The information is provided
in a tabular format and fully referenced.
2014 Sales of
Branded Filgrastim, Lenograstim & Pegfilgrastim Products
Filgrastim & Lenograstim: Originator, Biosimilar
& Biosuperior Products in EU
Filgrastim: Originator, Biosimilar & Biosuperior
Products in USA
Filgrastim, Lenograstim & Nartograstim:
Originator, Biosimilar & Biosuperior Products in Japan
Filgrastim: Biosimilar Products in India, Pakistan
& Bangladesh
Filgrastim: Biosimilar Products in China & Taiwan
Filgrastim: Biosimilar Products in South Korea
Filgrastim & Lenograstim: Biosimilar Products in
Latin America
Filgrastim: Biosimilar Products in Other Less
Regulated Markets
Pegfilgrastim: Originator, Biosimilar &
Biosuperior Products in EU
Pegfilgrastim: Originator, Biosimilar &
Biosuperior Products in USA
Pegfilgrastim: Originator, Biosimilar &
Biosuperior Products in Japan
Pegfilgrastim: Biosimilar Products in India &
Pakistan
Pegfilgrastim: Biosimilar & Biosuperior Products
in China & Taiwan
Pegfilgrastim: Biosimilar & Biosuperior Products
in South Korea
Pegfilgrastim: Biosimilar Products in Other Less
Regulated Markets
GM-CSF: Sargramostim Originator & Biosimilar
Products worldwide
GM-CSF: Molgramostim Originator & Biosimilar
Products worldwide
Corporate Filgrastim & Pegfilgrastim Biosimilar
& Biosuperior Portfolios
For
further information on this report, please visit-
http://mrr.cm/oky
Related Reports:
1st- Competitor Analysis:
Interleukin-17/Receptor (IL-17/R) Antagonists - visit at: http://mrr.cm/okF
2nd- 2014 Sales of Recombinant Therapeutic Antibodies
& Proteins - visit at: http://mrr.cm/okt
Yearly/Quarterly
Report Subscription: http://www.marketresearchreports.com/subscriptions
No comments:
Post a Comment
Note: only a member of this blog may post a comment.